EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review

Raluca-Elena Marica, Adelina Băloi, Marius Păpurică iD, Ciprian-Mihai Gândac, Claudiu-Rafael Bârsac, Justin-Ștefan Paraschiv, Gabi-Valeriu Dincă, Cristian-Daniel Marica, Bogdan Socea iD, Ovidiu-Horea Bedreag iD, Dorel Săndesc, Gabriel-Petre Gorecki iD

Diagnostics · 11.08.2026 · 16 (16) · 2524

DOI: 10.3390/diagnostics16162524 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 11.08.2026. Verfasst von Raluca-Elena Marica und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babeș University of Medicine and Pharmacy Timișoara, “Victor Babes” University of Medicine and Pharmacy Timisoara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Esophagogastric cancer (EGC), encompassing oesophageal, gastroesophageal junction (GEJ), and proximal gastric malignancies, remains a major contributor to global cancer mortality. Neoadjuvant therapy, chemotherapy (CT) or chemoradiotherapy (CRT) is now standard for locally advanced, resectable disease. However, variability in treatment response and survival outcomes continues to challenge therapeutic optimisation.

Methods

This systematic review followed the PRISMA 2020 guidelines and included studies published between January 2020 and September 2025. Eligible studies enrolled adult patients with resectable EGC treated with neoadjuvant CT or CRT, reporting data on pathological response (pathological complete response (pCR) or tumour regression grade (TRG)) and survival outcomes [overall survival (OS), disease-free survival (DFS)]. Sixty studies (18 randomised controlled trials and 42 cohort analyses) were included for qualitative synthesis.

Results

Across all regimens, pCR rates ranged from 8% to 49%, with CRT achieving higher pCR (mean 33%) and major TRG response (63%) compared to CT alone (pCR 22%, TRG 48%). Immunotherapy-enhanced protocols (IO-CRT and IO-CT) demonstrated the most promising outcomes, reaching mean pCR rates up to 48–50%. Patients with complete or major regression consistently achieved superior OS and DFS, confirming pathological response as a consistent prognostic marker for long-term survival. Significant clinical heterogeneity was observed across histological subtypes (SCC vs. AC), treatment intensity, and surgical timing, while methodological heterogeneity stemmed from variations in TRG systems, follow-up duration, and reporting standards.

Conclusions

Pathological response is consistently associated with survival following neoadjuvant therapy in EGC, yet its predictive power is modulated by tumour histology and treatment modality. Standardisation of TRG assessment, integration of molecular biomarkers, and harmonisation of study design are essential for improving comparability and advancing personalised, multimodal strategies in oesophagogastric oncology.

Schlagwörter

Stichwörter der Autor:innen

chemoradiotherapyesophagogastric cancerimmunotherapyneoadjuvant therapypathological complete responsesurvival outcomestumour regression grade

Autor:innen und Institutionen

  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Department of Anesthesia and Intensive Care, Victor Babeș University of Medicine and Pharmacy, 300041 Timișoara, Romania.
  • Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
  • Department of General Surgery, Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
  • Department of General Surgery, CF 2 Clinical Hospital, 011464 Bucharest, Romania.
  • Department of General Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.

ORCID-Profile: Marius Păpurică, Bogdan Socea, Ovidiu-Horea Bedreag, Gabriel-Petre Gorecki

Förderung

  • Victor Babeș University of Medicine and Pharmacy Timișoara
  • “Victor Babes” University of Medicine and Pharmacy Timisoara

Zitieren

APA

Marica, R. E., Băloi, A., Păpurică, M., Gândac, C. M., Bârsac, C. R., Paraschiv, J. Ș., Dincă, G. V., Marica, C. D., Socea, B., Bedreag, O. H., Săndesc, D., & Gorecki, G. P. (2026). Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review. Diagnostics, 16(16), 2524. https://doi.org/10.3390/diagnostics16162524

Vancouver

Marica RE, Băloi A, Păpurică M, Gândac CM, Bârsac CR, Paraschiv JȘ, et al. Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review. Diagnostics. 2026;16(16):2524. doi:10.3390/diagnostics16162524

BibTeX
@article{Marica2026,
  author = {Marica, Raluca-Elena and Băloi, Adelina and Păpurică, Marius and Gândac, Ciprian-Mihai and Bârsac, Claudiu-Rafael and Paraschiv, Justin-Ștefan and Dincă, Gabi-Valeriu and Marica, Cristian-Daniel and Socea, Bogdan and Bedreag, Ovidiu-Horea and Săndesc, Dorel and Gorecki, Gabriel-Petre},
  title = {Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {16},
  pages = {2524},
  doi = {10.3390/diagnostics16162524}
}
Kostenlos starten →